Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Stock Competitors & Peer Comparison
See (RCDTF) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RCDTF | $65.44 | +26.82% | 13.3B | 28.58 | $2.29 | +3.08% |
| BMYMP | $1,002.93 | +0.29% | 2T | 4457.47 | $0.23 | +4.11% |
| RHHBF | $483.97 | -0.62% | 385.2B | 23.20 | $20.86 | +2.27% |
| RHHBY | $59.18 | +0.00% | 382.3B | 22.74 | $2.61 | +1.45% |
| RHHVF | $477.44 | +0.00% | 382.1B | 23.04 | $20.83 | +2.39% |
| NVSEF | $166.34 | +2.86% | 324.8B | 23.77 | $7.16 | +2.39% |
| AZNCF | $204.20 | -2.12% | 316.6B | 33.86 | $6.03 | +1.51% |
| GLAXF | $31.48 | +0.90% | 118.6B | 15.56 | $1.89 | +2.83% |
| SNYNF | $93.97 | -3.89% | 115B | 19.76 | $4.81 | +4.64% |
| CHGCY | $30.75 | -4.24% | 109.4B | 38.66 | $0.86 | +2.56% |
Stock Comparison
RCDTF vs BMYMP Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, BMYMP has a market cap of 2T. Regarding current trading prices, RCDTF is priced at $65.44, while BMYMP trades at $1,002.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas BMYMP's P/E ratio is 4457.47. In terms of profitability, RCDTF's ROE is +0.21%, compared to BMYMP's ROE of +0.39%. Regarding short-term risk, RCDTF is more volatile compared to BMYMP. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check BMYMP's competition here
RCDTF vs RHHBF Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, RHHBF has a market cap of 385.2B. Regarding current trading prices, RCDTF is priced at $65.44, while RHHBF trades at $483.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas RHHBF's P/E ratio is 23.20. In terms of profitability, RCDTF's ROE is +0.21%, compared to RHHBF's ROE of +0.29%. Regarding short-term risk, RCDTF is more volatile compared to RHHBF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check RHHBF's competition here
RCDTF vs RHHBY Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, RHHBY has a market cap of 382.3B. Regarding current trading prices, RCDTF is priced at $65.44, while RHHBY trades at $59.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas RHHBY's P/E ratio is 22.74. In terms of profitability, RCDTF's ROE is +0.21%, compared to RHHBY's ROE of +0.29%. Regarding short-term risk, RCDTF is more volatile compared to RHHBY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check RHHBY's competition here
RCDTF vs RHHVF Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, RHHVF has a market cap of 382.1B. Regarding current trading prices, RCDTF is priced at $65.44, while RHHVF trades at $477.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas RHHVF's P/E ratio is 23.04. In terms of profitability, RCDTF's ROE is +0.21%, compared to RHHVF's ROE of +0.41%. Regarding short-term risk, RCDTF is more volatile compared to RHHVF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check RHHVF's competition here
RCDTF vs NVSEF Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, NVSEF has a market cap of 324.8B. Regarding current trading prices, RCDTF is priced at $65.44, while NVSEF trades at $166.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas NVSEF's P/E ratio is 23.77. In terms of profitability, RCDTF's ROE is +0.21%, compared to NVSEF's ROE of +0.33%. Regarding short-term risk, RCDTF is more volatile compared to NVSEF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check NVSEF's competition here
RCDTF vs AZNCF Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, AZNCF has a market cap of 316.6B. Regarding current trading prices, RCDTF is priced at $65.44, while AZNCF trades at $204.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas AZNCF's P/E ratio is 33.86. In terms of profitability, RCDTF's ROE is +0.21%, compared to AZNCF's ROE of +0.23%. Regarding short-term risk, RCDTF is more volatile compared to AZNCF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check AZNCF's competition here
RCDTF vs GLAXF Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, GLAXF has a market cap of 118.6B. Regarding current trading prices, RCDTF is priced at $65.44, while GLAXF trades at $31.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas GLAXF's P/E ratio is 15.56. In terms of profitability, RCDTF's ROE is +0.21%, compared to GLAXF's ROE of +0.37%. Regarding short-term risk, RCDTF is more volatile compared to GLAXF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check GLAXF's competition here
RCDTF vs SNYNF Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, SNYNF has a market cap of 115B. Regarding current trading prices, RCDTF is priced at $65.44, while SNYNF trades at $93.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas SNYNF's P/E ratio is 19.76. In terms of profitability, RCDTF's ROE is +0.21%, compared to SNYNF's ROE of +0.15%. Regarding short-term risk, RCDTF is more volatile compared to SNYNF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check SNYNF's competition here
RCDTF vs CHGCY Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, CHGCY has a market cap of 109.4B. Regarding current trading prices, RCDTF is priced at $65.44, while CHGCY trades at $30.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas CHGCY's P/E ratio is 38.66. In terms of profitability, RCDTF's ROE is +0.21%, compared to CHGCY's ROE of +0.23%. Regarding short-term risk, RCDTF is more volatile compared to CHGCY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check CHGCY's competition here
RCDTF vs CHGCF Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, CHGCF has a market cap of 105.3B. Regarding current trading prices, RCDTF is priced at $65.44, while CHGCF trades at $61.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas CHGCF's P/E ratio is 37.22. In terms of profitability, RCDTF's ROE is +0.21%, compared to CHGCF's ROE of +0.22%. Regarding short-term risk, RCDTF is more volatile compared to CHGCF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check CHGCF's competition here
RCDTF vs BAYRY Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, BAYRY has a market cap of 49.3B. Regarding current trading prices, RCDTF is priced at $65.44, while BAYRY trades at $13.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas BAYRY's P/E ratio is -209.17. In terms of profitability, RCDTF's ROE is +0.21%, compared to BAYRY's ROE of -0.01%. Regarding short-term risk, RCDTF is more volatile compared to BAYRY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check BAYRY's competition here
RCDTF vs OTSKY Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, OTSKY has a market cap of 37.6B. Regarding current trading prices, RCDTF is priced at $65.44, while OTSKY trades at $33.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas OTSKY's P/E ratio is 15.39. In terms of profitability, RCDTF's ROE is +0.21%, compared to OTSKY's ROE of +0.13%. Regarding short-term risk, RCDTF is more volatile compared to OTSKY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check OTSKY's competition here
RCDTF vs OTSKF Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, OTSKF has a market cap of 37.1B. Regarding current trading prices, RCDTF is priced at $65.44, while OTSKF trades at $70.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas OTSKF's P/E ratio is 14.50. In terms of profitability, RCDTF's ROE is +0.21%, compared to OTSKF's ROE of +0.13%. Regarding short-term risk, RCDTF is more volatile compared to OTSKF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check OTSKF's competition here
RCDTF vs DSNKY Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, DSNKY has a market cap of 35.5B. Regarding current trading prices, RCDTF is priced at $65.44, while DSNKY trades at $18.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas DSNKY's P/E ratio is 19.37. In terms of profitability, RCDTF's ROE is +0.21%, compared to DSNKY's ROE of +0.19%. Regarding short-term risk, RCDTF is more volatile compared to DSNKY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check DSNKY's competition here
RCDTF vs DSKYF Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, DSKYF has a market cap of 34.8B. Regarding current trading prices, RCDTF is priced at $65.44, while DSKYF trades at $18.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas DSKYF's P/E ratio is 19.19. In terms of profitability, RCDTF's ROE is +0.21%, compared to DSKYF's ROE of +0.19%. Regarding short-term risk, RCDTF is more volatile compared to DSKYF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check DSKYF's competition here
RCDTF vs ALPMF Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, ALPMF has a market cap of 29.4B. Regarding current trading prices, RCDTF is priced at $65.44, while ALPMF trades at $15.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas ALPMF's P/E ratio is 37.28. In terms of profitability, RCDTF's ROE is +0.21%, compared to ALPMF's ROE of +0.20%. Regarding short-term risk, RCDTF is more volatile compared to ALPMF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check ALPMF's competition here
RCDTF vs ALPMY Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, ALPMY has a market cap of 28.6B. Regarding current trading prices, RCDTF is priced at $65.44, while ALPMY trades at $16.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas ALPMY's P/E ratio is 35.51. In terms of profitability, RCDTF's ROE is +0.21%, compared to ALPMY's ROE of +0.20%. Regarding short-term risk, RCDTF is more volatile compared to ALPMY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check ALPMY's competition here
RCDTF vs ORINY Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, ORINY has a market cap of 22.8B. Regarding current trading prices, RCDTF is priced at $65.44, while ORINY trades at $40.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas ORINY's P/E ratio is 19.23. In terms of profitability, RCDTF's ROE is +0.21%, compared to ORINY's ROE of +0.47%. Regarding short-term risk, RCDTF is more volatile compared to ORINY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check ORINY's competition here
RCDTF vs GIKLY Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, GIKLY has a market cap of 17B. Regarding current trading prices, RCDTF is priced at $65.44, while GIKLY trades at $6.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas GIKLY's P/E ratio is 20.16. In terms of profitability, RCDTF's ROE is +0.21%, compared to GIKLY's ROE of +0.07%. Regarding short-term risk, RCDTF is more volatile compared to GIKLY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check GIKLY's competition here
RCDTF vs CHJTF Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, CHJTF has a market cap of 15.9B. Regarding current trading prices, RCDTF is priced at $65.44, while CHJTF trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas CHJTF's P/E ratio is 27.80. In terms of profitability, RCDTF's ROE is +0.21%, compared to CHJTF's ROE of +0.06%. Regarding short-term risk, RCDTF is more volatile compared to CHJTF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check CHJTF's competition here
RCDTF vs CSPCY Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, CSPCY has a market cap of 15.5B. Regarding current trading prices, RCDTF is priced at $65.44, while CSPCY trades at $5.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas CSPCY's P/E ratio is 28.29. In terms of profitability, RCDTF's ROE is +0.21%, compared to CSPCY's ROE of +0.06%. Regarding short-term risk, RCDTF is more volatile compared to CSPCY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check CSPCY's competition here
RCDTF vs ORINF Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, ORINF has a market cap of 11.1B. Regarding current trading prices, RCDTF is priced at $65.44, while ORINF trades at $78.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas ORINF's P/E ratio is 18.71. In terms of profitability, RCDTF's ROE is +0.21%, compared to ORINF's ROE of +0.47%. Regarding short-term risk, RCDTF is more volatile compared to ORINF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check ORINF's competition here
RCDTF vs KYKOF Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, KYKOF has a market cap of 8.8B. Regarding current trading prices, RCDTF is priced at $65.44, while KYKOF trades at $16.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas KYKOF's P/E ratio is 20.10. In terms of profitability, RCDTF's ROE is +0.21%, compared to KYKOF's ROE of +0.08%. Regarding short-term risk, RCDTF is more volatile compared to KYKOF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check KYKOF's competition here
RCDTF vs GIFLF Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, GIFLF has a market cap of 8.8B. Regarding current trading prices, RCDTF is priced at $65.44, while GIFLF trades at $12.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas GIFLF's P/E ratio is 20.16. In terms of profitability, RCDTF's ROE is +0.21%, compared to GIFLF's ROE of +0.07%. Regarding short-term risk, RCDTF is more volatile compared to GIFLF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check GIFLF's competition here
RCDTF vs GIFOF Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, GIFOF has a market cap of 8.7B. Regarding current trading prices, RCDTF is priced at $65.44, while GIFOF trades at $8.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas GIFOF's P/E ratio is 13.83. In terms of profitability, RCDTF's ROE is +0.21%, compared to GIFOF's ROE of +0.07%. Regarding short-term risk, RCDTF is more volatile compared to GIFOF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check GIFOF's competition here
RCDTF vs OPHLY Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, OPHLY has a market cap of 7.9B. Regarding current trading prices, RCDTF is priced at $65.44, while OPHLY trades at $5.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas OPHLY's P/E ratio is 23.27. In terms of profitability, RCDTF's ROE is +0.21%, compared to OPHLY's ROE of +0.08%. Regarding short-term risk, RCDTF is more volatile compared to OPHLY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check OPHLY's competition here
RCDTF vs OPHLF Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, OPHLF has a market cap of 7.8B. Regarding current trading prices, RCDTF is priced at $65.44, while OPHLF trades at $16.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas OPHLF's P/E ratio is 23.52. In terms of profitability, RCDTF's ROE is +0.21%, compared to OPHLF's ROE of +0.08%. Regarding short-term risk, RCDTF is more volatile compared to OPHLF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check OPHLF's competition here
RCDTF vs DPHAY Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, DPHAY has a market cap of 5.6B. Regarding current trading prices, RCDTF is priced at $65.44, while DPHAY trades at $98.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas DPHAY's P/E ratio is -155.56. In terms of profitability, RCDTF's ROE is +0.21%, compared to DPHAY's ROE of -0.04%. Regarding short-term risk, RCDTF is more volatile compared to DPHAY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check DPHAY's competition here
RCDTF vs SNPHY Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, SNPHY has a market cap of 3.6B. Regarding current trading prices, RCDTF is priced at $65.44, while SNPHY trades at $11.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas SNPHY's P/E ratio is 18.34. In terms of profitability, RCDTF's ROE is +0.21%, compared to SNPHY's ROE of +0.11%. Regarding short-term risk, RCDTF is more volatile compared to SNPHY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check SNPHY's competition here
RCDTF vs PTKFF Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, PTKFF has a market cap of 3.2B. Regarding current trading prices, RCDTF is priced at $65.44, while PTKFF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas PTKFF's P/E ratio is N/A. In terms of profitability, RCDTF's ROE is +0.21%, compared to PTKFF's ROE of +0.15%. Regarding short-term risk, RCDTF is more volatile compared to PTKFF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check PTKFF's competition here
RCDTF vs HAWPF Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, HAWPF has a market cap of 3.1B. Regarding current trading prices, RCDTF is priced at $65.44, while HAWPF trades at $14.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas HAWPF's P/E ratio is 15.74. In terms of profitability, RCDTF's ROE is +0.21%, compared to HAWPF's ROE of +0.06%. Regarding short-term risk, RCDTF is more volatile compared to HAWPF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check HAWPF's competition here
RCDTF vs SNPHF Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, SNPHF has a market cap of 3.1B. Regarding current trading prices, RCDTF is priced at $65.44, while SNPHF trades at $9.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas SNPHF's P/E ratio is 16.12. In terms of profitability, RCDTF's ROE is +0.21%, compared to SNPHF's ROE of +0.14%. Regarding short-term risk, RCDTF is more volatile compared to SNPHF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check SNPHF's competition here
RCDTF vs VRBCF Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, VRBCF has a market cap of 2.9B. Regarding current trading prices, RCDTF is priced at $65.44, while VRBCF trades at $346.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas VRBCF's P/E ratio is 17.04. In terms of profitability, RCDTF's ROE is +0.21%, compared to VRBCF's ROE of +0.13%. Regarding short-term risk, RCDTF is more volatile compared to VRBCF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check VRBCF's competition here
RCDTF vs HAWPY Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, HAWPY has a market cap of 2.7B. Regarding current trading prices, RCDTF is priced at $65.44, while HAWPY trades at $49.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas HAWPY's P/E ratio is 13.70. In terms of profitability, RCDTF's ROE is +0.21%, compared to HAWPY's ROE of +0.06%. Regarding short-term risk, RCDTF is more volatile compared to HAWPY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check HAWPY's competition here
RCDTF vs CMOPF Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, CMOPF has a market cap of 2.4B. Regarding current trading prices, RCDTF is priced at $65.44, while CMOPF trades at $159.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas CMOPF's P/E ratio is 35.85. In terms of profitability, RCDTF's ROE is +0.21%, compared to CMOPF's ROE of +0.12%. Regarding short-term risk, RCDTF is more volatile compared to CMOPF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check CMOPF's competition here
RCDTF vs LYPHF Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, LYPHF has a market cap of 1.5B. Regarding current trading prices, RCDTF is priced at $65.44, while LYPHF trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas LYPHF's P/E ratio is 18.88. In terms of profitability, RCDTF's ROE is +0.21%, compared to LYPHF's ROE of +0.03%. Regarding short-term risk, RCDTF is more volatile compared to LYPHF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check LYPHF's competition here
RCDTF vs TGRNF Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, TGRNF has a market cap of 704.4M. Regarding current trading prices, RCDTF is priced at $65.44, while TGRNF trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas TGRNF's P/E ratio is 11.00. In terms of profitability, RCDTF's ROE is +0.21%, compared to TGRNF's ROE of +0.06%. Regarding short-term risk, RCDTF is more volatile compared to TGRNF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check TGRNF's competition here
RCDTF vs JCRRF Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, JCRRF has a market cap of 508.7M. Regarding current trading prices, RCDTF is priced at $65.44, while JCRRF trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas JCRRF's P/E ratio is -34.75. In terms of profitability, RCDTF's ROE is +0.21%, compared to JCRRF's ROE of -0.07%. Regarding short-term risk, RCDTF is more volatile compared to JCRRF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check JCRRF's competition here
RCDTF vs MAYNF Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, MAYNF has a market cap of 150.7M. Regarding current trading prices, RCDTF is priced at $65.44, while MAYNF trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas MAYNF's P/E ratio is -2.35. In terms of profitability, RCDTF's ROE is +0.21%, compared to MAYNF's ROE of -0.23%. Regarding short-term risk, RCDTF is more volatile compared to MAYNF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check MAYNF's competition here
RCDTF vs PTKFY Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, PTKFY has a market cap of 15.1M. Regarding current trading prices, RCDTF is priced at $65.44, while PTKFY trades at $13.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas PTKFY's P/E ratio is 14.61. In terms of profitability, RCDTF's ROE is +0.21%, compared to PTKFY's ROE of +0.15%. Regarding short-term risk, RCDTF is more volatile compared to PTKFY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check PTKFY's competition here
RCDTF vs PSYGF Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, PSYGF has a market cap of 2M. Regarding current trading prices, RCDTF is priced at $65.44, while PSYGF trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas PSYGF's P/E ratio is -0.17. In terms of profitability, RCDTF's ROE is +0.21%, compared to PSYGF's ROE of +3.04%. Regarding short-term risk, RCDTF is more volatile compared to PSYGF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check PSYGF's competition here
RCDTF vs CRXTQ Comparison February 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 13.3B. In comparison, CRXTQ has a market cap of 72.8K. Regarding current trading prices, RCDTF is priced at $65.44, while CRXTQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 28.58, whereas CRXTQ's P/E ratio is -0.00. In terms of profitability, RCDTF's ROE is +0.21%, compared to CRXTQ's ROE of +0.33%. Regarding short-term risk, RCDTF is more volatile compared to CRXTQ. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check CRXTQ's competition here